Morphosys Ag Share Price: MOR (Morphosys Ag) Stock Price Today & Updates | INDmoney

Question 1

What is Morphosys Ag share price today?

Accepted Answer

Morphosys Ag (MOR) share price today is {{live_price}}.

Question 2

Can Indians buy Morphosys Ag shares?

Accepted Answer

Yes, Indians can invest in the Morphosys Ag (MOR) from India.

With INDmoney, you can buy Morphosys Ag at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Morphosys Ag at zero transaction cost.

Question 3

How can I buy Morphosys Ag shares from India?

Accepted Answer

It is very easy to buy Morphosys Ag from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Morphosys Ag be purchased?

Accepted Answer

Yes, you can buy fractional shares of Morphosys Ag with INDmoney app.

Question 5

What are the documents required to start investing in Morphosys Ag stocks?

Accepted Answer

To start investing in Morphosys Ag, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Morphosys Ag

Accepted Answer

Today’s highest price of Morphosys Ag (MOR) is {{1_rba_end}}.

Today’s lowest price of Morphosys Ag (MOR) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Morphosys Ag

Accepted Answer

Today's market capitalisation of Morphosys Ag MOR is 2.7B

Question 8

What is the 52 Week High and Low Range of Morphosys Ag

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Morphosys Ag is down from its 52 Week High?

Accepted Answer

Morphosys Ag (MOR) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Morphosys Ag is up from its 52 Week low?

Accepted Answer

Morphosys Ag (MOR) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Morphosys Ag?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Morphosys Ag

Accepted Answer

Dr. Jean-Paul  Kress M.D. is the current Chief Executive Officer (CEO) of Morphosys Ag.

Period	Morphosys Ag	Sector (Health Care)	Index (Russel 2000)
3 Months	88.11%	1.9%	0.0%
6 Months	162.21%	10.7%	0.0%
1 Year	234.69%	4.6%	-1.1%
3 Years	-23.49%	14.2%	-22.1%

Market Capitalization	2.7B
Book Value	$1.3
Earnings Per Share (EPS)	-1.47
Wall Street Target Price	15.46

Profit Margin	-79.63%
Operating Margin TTM	-129.31%

Return On Assets TTM	-6.82%
Return On Equity TTM	-183.8%

Revenue TTM	238.3M
Revenue Per Share TTM	1.74
Quarterly Revenue Growth YOY	-27.700000000000003%
Gross Profit TTM	229.6M
EBITDA	-235.4M
Diluted Eps TTM	-1.47
Quarterly Earnings Growth YOY	-0.87

Morphosys Ag (MOR)

Decreasing Revenue

Increasing Net Profit

Vs NVO

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Institutional Holdings

Company Information

Discover More

FAQs

EPS Estimate Current Year	-3.15
EPS Estimate Next Year	-1.87
EPS Estimate Current Quarter	0.09
EPS Estimate Next Quarter	-0.34

	FY18	Y/Y Change
Revenue	87.5M	↑ 14.45%
Net Income	-64.3M	↓ 19.55%
Net Profit Margin	-73.48%	↑ 31.06%

	FY19	Y/Y Change
Revenue	80.4M	↓ 6.13%
Net Income	-115.4M	↑ 83.39%
Net Profit Margin	-143.56%	↓ 70.08%

	FY20	Y/Y Change
Revenue	403.1M	↑ 356.69%
Net Income	120.4M	↓ 195.03%
Net Profit Margin	29.87%	↑ 173.43%

	FY21	Y/Y Change
Revenue	203.4M	↓ 45.19%
Net Income	-582.7M	↓ 625.59%
Net Profit Margin	-286.47%	↓ 316.34%

	FY22	Y/Y Change
Revenue	298.1M	↑ 54.94%
Net Income	-161.8M	↓ 70.64%
Net Profit Margin	-54.29%	↑ 232.18%

	FY23	Y/Y Change
Revenue	238.3M	↓ 14.37%
Net Income	-189.7M	↑ 25.6%
Net Profit Margin	-79.63%	↓ 25.34%

	Q3 FY22	Q/Q Change
Revenue	94.1M	↑ 61.0%
Net Income	-120.8M	↓ 47.7%
Net Profit Margin	-128.42%	↑ 266.91%

	Q4 FY22	Q/Q Change
Revenue	87.5M	↓ 14.66%
Net Income	352.9M	↓ 368.06%
Net Profit Margin	403.4%	↑ 531.82%

	Q1 FY23	Q/Q Change
Revenue	68.0M	↓ 23.69%
Net Income	-47.9M	↓ 113.32%
Net Profit Margin	-70.42%	↓ 473.82%

	FY18	Y/Y Change
Total Assets	616.4M	↑ 29.7%
Total Liabilities	57.6M	↓ 11.17%

	FY19	Y/Y Change
Total Assets	556.1M	↓ 7.86%
Total Liabilities	114.0M	↑ 101.9%

	FY20	Y/Y Change
Total Assets	2.0B	↑ 234.28%
Total Liabilities	1.3B	↑ 920.46%

	FY21	Y/Y Change
Total Assets	2.9B	↑ 54.04%
Total Liabilities	2.6B	↑ 122.64%

	Q2 FY23	Q/Q Change
Revenue	58.0M	↓ 14.69%
Net Income	-80.7M	↑ 68.54%
Net Profit Margin	-139.13%	↓ 68.71%

	Q3 FY23	Q/Q Change
Revenue	63.8M	↑ 20.0%
Net Income	-119.6M	↑ 61.69%
Net Profit Margin	-187.46%	↓ 48.33%

	Q4 FY23	Q/Q Change
Revenue	59.1M	↓ 7.4%
Net Income	48.3M	↓ 140.36%
Net Profit Margin	81.7%	↑ 269.16%

	FY18	Y/Y Change
Operating Cash Flow	-38.1M	↓ 13.46%
Investing Cash Flow	-203.4M	↓ 639.74%
Financing Cash Flow	205.3M	↑ 2095.57%

	FY19	Y/Y Change
Operating Cash Flow	-89.8M	↑ 140.88%
Investing Cash Flow	89.0M	↓ 144.72%
Financing Cash Flow	395.7K	↓ 99.8%

	FY20	Y/Y Change
Operating Cash Flow	43.4M	↓ 144.01%
Investing Cash Flow	-1.1B	↓ 1206.67%
Financing Cash Flow	1.1B	↑ 256719.36%

	FY21	Y/Y Change
Operating Cash Flow	-545.2M	↓ 1465.04%
Investing Cash Flow	-941.1M	↓ 5.53%
Financing Cash Flow	1.5B	↑ 45.83%

	FY22	Y/Y Change
Operating Cash Flow	-392.8M	↓ 23.83%
Investing Cash Flow	369.6M	↓ 141.52%
Financing Cash Flow	333.6M	↓ 76.46%

	Q3 FY22	Q/Q Change
Operating Cash Flow	-21.4M	↓ 76.84%
Investing Cash Flow	55.6M	↓ 42.76%
Financing Cash Flow	289.1M	↑ 15027.06%

	Q4 FY22	Q/Q Change
Operating Cash Flow	-112.8M	↑ 382.81%
Investing Cash Flow	79.7M	↑ 31.58%
Financing Cash Flow	4.3M	↓ 98.64%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-77.7M	↓ 32.37%
Investing Cash Flow	25.4M	↓ 68.77%
Financing Cash Flow	-49.4M	↓ 1234.55%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-137.4M	↑ 76.83%
Investing Cash Flow	25.4M	↑ 0.0%
Financing Cash Flow	-5.1M	↓ 89.69%

	Q3 FY23	Q/Q Change
Operating Cash Flow	-33.7M	↓ 73.26%
Investing Cash Flow	39.4M	↑ 69.38%
Financing Cash Flow	-1.7M	↓ 63.36%

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Morphosys Ag	-0.61%	162.21%	234.69%	-23.49%	-27.2%
Moderna, Inc.	-2.26%	35.27%	-21.9%	-39.25%	318.83%
Regeneron Pharmaceuticals, Inc.	-5.59%	12.81%	13.84%	81.04%	166.5%
Novo Nordisk A/s	-0.32%	31.91%	50.92%	247.21%	431.9%
Vertex Pharmaceuticals Incorporated	-2.67%	9.62%	21.65%	86.62%	134.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Morphosys Ag	24.71	NA	NA	-3.15	-1.84	-0.07	NA	1.3
Moderna, Inc.	24.73	NA	0.0	-7.22	-0.29	-0.12	NA	36.27
Regeneron Pharmaceuticals, Inc.	25.9	25.9	1.46	45.02	0.16	0.08	NA	242.47
Novo Nordisk A/s	47.09	47.09	2.4	3.33	0.88	0.23	0.01	23.9
Vertex Pharmaceuticals Incorporated	28.81	28.81	0.53	16.76	0.23	0.13	NA	68.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Morphosys Ag	Buy	$2.7B	-27.2%	24.71	-79.63%
Moderna, Inc.	Buy	$40.0B	318.83%	24.73	-68.84%
Regeneron Pharmaceuticals, Inc.	Buy	$98.8B	166.5%	25.9	30.14%
Novo Nordisk A/s	Buy	$558.9B	431.9%	47.09	36.03%
Vertex Pharmaceuticals Incorporated	Buy	$103.4B	134.62%	28.81	36.68%

Organization	Morphosys Ag
Employees	524
CEO	Dr. Jean-Paul Kress M.D.
Industry	Health Technology